VKORC1 -1639G>A PCR Assay
The Viennalab VKORC1 -1639G>A RealFast Assay determines the three possible genotypes of the VKORC1 promoter variant -1639G>A in a human genomic DNA extract by real-time PCR: GG, GA and AA. This tag-SNP accounts for a large part of the variation between patients in the dose requirement for oral anticoagulants such as warfarin, phenprocoumon and acenocoumarol. VKORC1 is the target of the vitamin K antagonists prescribed for the prevention and treatment of thromboembolic disorders. These drugs have a narrow therapeutic range, and homozygous carriers of the A allele need a lower dose than carriers of the G allele.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
- Detects the VKORC1 promoter variant -1639G>A
- Distinguishes the GG, GA and AA genotypes
- Supports dosing of warfarin, phenprocoumon and acenocoumarol
- Real-time PCR with variant-specific probes
- Whole peripheral blood, dried blood spots, buccal swabs or saliva
- 32 or 100 reactions per kit, REF 7-193 and REF 7-190
The Viennalab VKORC1 -1639G>A RealFast Assay determines the genotype of the VKORC1 promoter variant -1639G>A, the single strongest genetic predictor of the dose requirement for coumarin anticoagulants.
Clinical background
Vitamin K epoxide reductase, the product of VKORC1, is the target of the vitamin K antagonists used to prevent and treat thromboembolic disorders. These drugs have a narrow therapeutic range and a wide variation in dose response, which complicates the start of treatment: too high a dose causes bleeding, too low a dose leaves the patient at risk of thromboembolism. The -1639G>A variant lies in the promoter and lowers expression of the gene.
Interpretation
The assay distinguishes the GG genotype (normal dose requirement), GA (intermediate) and AA (low). Homozygous carriers of the A allele need a lower dose of warfarin, phenprocoumon or acenocoumarol than heterozygous carriers or carriers of two G alleles. Empirical dosing leads to repeated dose changes while the international normalized ratio (INR) fluctuates; dosing guided by the genotype shortens that phase.
Method
The assay uses real-time PCR with the RealFast 2x Genotyping Mix and the VKORC1 -1639G>A Assay Mix. A GG-control and an AA-control are supplied. DNA isolated from whole peripheral blood, dried blood spots, buccal swabs or saliva can be used, and DNA extraction reagents are not supplied with the kit; ViennaLab recommends the Spin Micro DNA Extraction Kit (REF 2-020), ordered separately.
- RealFast 2x Genotyping Mix (white cap, 1000 / 320 µl)
- VKORC1 -1639G>A Assay Mix (purple cap, 550 µl)
- VKORC1 -1639G>A GG-Control (green cap, 75 µl)
- VKORC1 -1639G>A AA-Control (red cap, 75 µl)
REF 7-190 (100 reactions) and REF 7-193 (32 reactions). DNA extraction reagents are not supplied with the kit. ViennaLab recommends the Spin Micro DNA Extraction Kit (REF 2-020), which is ordered separately.
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Instructions for Use
Frequently paired with this kit
Other assays and instruments lab teams add alongside the VKORC1 -1639G>A PCR Assay.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
